Treatment Patterns and Healthcare Resource Utilization in Ruxolitinib-Treated Patients with Myelofibrosis with and Without Anemia: a Real-World Analysis
Annals of Hematology（2025）
Key words
Anemia,Cost,Healthcare burden,JAK inhibitor,Myelofibrosis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined